Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the first patient dosing in a Phase I clinical study in China for its MRX-8, a new drug against gram-negative drug-resistant bacteria. This marks a significant milestone in the development of MRX-8, which aims to address the growing challenge of multi-drug resistant infections.
MRX-8 Profile
MRX-8 is an innovative polymyxin antibiotic with potent activity against Gram-negative pathogens. It is designed to treat infections caused by multi-drug resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. The drug concluded Phase I clinical trials in the United States last month, demonstrating acceptable safety and pharmacokinetic characteristics at the expected clinical treatment dose in American healthy subjects.
Future Development Plans
The initiation of the Phase I clinical study in China underscores MicuRx Pharmaceuticals’ commitment to advancing MRX-8 as a potential solution for treating drug-resistant bacterial infections globally. This study will provide additional data on the drug’s safety and efficacy, supporting its development for broader clinical use.-Fineline Info & Tech
